159 related articles for article (PubMed ID: 32166534)
21. Comparison of Two Weight-Based Desmopressin Dosing Strategies for Spontaneous Bleeding.
Franquiz MJ; Hines MC; Yeung SYA
Ann Pharmacother; 2018 Jun; 52(6):527-532. PubMed ID: 29332421
[TBL] [Abstract][Full Text] [Related]
22. Clinical assessment of efficacy and safety of DDAVP.
Miesbach W; Krekeler S; Dück O; Llugaliu B; Asmelash G; Schüttrumpf J; Alesci SR; Grossmann R
Hamostaseologie; 2010 Nov; 30 Suppl 1():S172-5. PubMed ID: 21042675
[TBL] [Abstract][Full Text] [Related]
23. The clinical significance of different routes of desmopressin (DDAVP) administration in various bleeding disorders.
Mörsdorf S; Köhler M; Leipnitz G; Wenzel E
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):503-7. PubMed ID: 2465962
[TBL] [Abstract][Full Text] [Related]
24. Convulsions and respiratory arrest in association with desmopressin administration for the treatment of a bleeding tonsil in a child with borderline haemophilia.
Francis JD; Leary T; Niblett DJ
Acta Anaesthesiol Scand; 1999 Sep; 43(8):870-3. PubMed ID: 10492420
[TBL] [Abstract][Full Text] [Related]
25. How do you treat bleeding disorders with desmopressin?
Ozgönenel B; Rajpurkar M; Lusher JM
Postgrad Med J; 2007 Mar; 83(977):159-63. PubMed ID: 17344569
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
27. Intraleucocyte platelet-activating factor levels in desmopressin-treated patients with haemophilia A and von Willebrand disease.
Kavakli K; Hüseyinov A; Coker I; Aydinok Y; Nisli G
Haemophilia; 2001 Sep; 7(5):482-9. PubMed ID: 11554936
[TBL] [Abstract][Full Text] [Related]
28. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery.
Hackmann T; Gascoyne RD; Naiman SC; Growe GH; Burchill LD; Jamieson WR; Sheps SB; Schechter MT; Townsend GE
N Engl J Med; 1989 Nov; 321(21):1437-43. PubMed ID: 2682243
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model.
Bonhomme F; Lecompte T; Samama CM; Godier A; Fontana P
Eur J Anaesthesiol; 2018 Mar; 35(3):208-214. PubMed ID: 29334511
[TBL] [Abstract][Full Text] [Related]
30. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.
Federici AB; Bucciarelli P; Castaman G; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Peyvandi F; Rodeghiero F; Mannucci PM
Blood; 2014 Jun; 123(26):4037-44. PubMed ID: 24786773
[TBL] [Abstract][Full Text] [Related]
31. Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers.
Steiner IM; Kaehler ST; Sauermann R; Rinösl H; Müller M; Joukhadar C
Int J Clin Pharmacol Ther; 2006 Apr; 44(4):172-9. PubMed ID: 16625986
[TBL] [Abstract][Full Text] [Related]
32. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
Guddati AK; Rosovsky RP; Van Cott EM; Kuter DJ
Int J Lab Hematol; 2019 Jun; 41(3):325-330. PubMed ID: 30735311
[TBL] [Abstract][Full Text] [Related]
33. The use of desmopressin in von Willebrand disease: the experience of the first 30 years (1977-2007).
Federici AB
Haemophilia; 2008 Jan; 14 Suppl 1():5-14. PubMed ID: 18173689
[TBL] [Abstract][Full Text] [Related]
34. Utilization and Effectiveness of Desmopressin Acetate After Cardiac Surgery Supplemented With Point-of-Care Hemostatic Testing: A Propensity-Score-Matched Analysis.
Orlov D; McCluskey SA; Callum J; Rao V; Moreno J; Karkouti K
J Cardiothorac Vasc Anesth; 2017 Jun; 31(3):883-895. PubMed ID: 28169116
[TBL] [Abstract][Full Text] [Related]
35. Use of desmopressin for unremitting epistaxis following septorhinoplasty and turbinectomy.
Faber C; Larson K; Amirlak B; Guyuron B
Plast Reconstr Surg; 2011 Dec; 128(6):728e-732e. PubMed ID: 22094773
[TBL] [Abstract][Full Text] [Related]
36. Significant hyponatremia following DDAVP administration in a healthy adult.
Humphries JE; Siragy H
Am J Hematol; 1993 Sep; 44(1):12-5. PubMed ID: 8342559
[TBL] [Abstract][Full Text] [Related]
37. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders.
Leissinger C; Carcao M; Gill JC; Journeycake J; Singleton T; Valentino L
Haemophilia; 2014 Mar; 20(2):158-67. PubMed ID: 23937614
[TBL] [Abstract][Full Text] [Related]
38. Desmopressin : safety considerations in patients with chronic renal disease.
Sica DA; Gehr TW
Drug Saf; 2006; 29(7):553-6. PubMed ID: 16808548
[No Abstract] [Full Text] [Related]
39. [Intravenous administration of deamino-D-arginine-vasopressin (DDAVP) to patients with hemophilia A and von Willebrand's disease].
Janczarski M; Ruszkowska I; Cetnarowicz H; Lopaciuk S
Acta Haematol Pol; 1990; 21(1):16-21. PubMed ID: 2260405
[TBL] [Abstract][Full Text] [Related]
40. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients.
Dunn AL; Powers JR; Ribeiro MJ; Rickles FR; Abshire TC
Haemophilia; 2000 Jan; 6(1):11-4. PubMed ID: 10632735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
